← All companies ← TAC Manual TAL → ← SXTC Pharmaceuticals TBPH →
TAK, Takeda Pharmaceutical Company Limited
Accordingly, Takeda presents both types of measures to provide investors with additional information to analyze Takeda's results of operations and financial condition and understand how Takeda's management assesses the same.
Core Operating Profit represents operating profit adjusted to exclude other operating expenses and income, amortization and impairment losses on intangible assets associated with products (including in-process R&D) and non-cash items or items unrelated to the underlying trends and business performance of Takeda's core operations.
The business
What it sells, where the money comes from, the kind of company it is.
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- Situation
- Cyclical. Margins collapse and recover repeatedly across the record; a single year, good or bad, misstates the through-cycle earning power.
- What moves the needle
- Gross margin has run about 69% and operating margin about 11% through the cycle, a wide spread between price and the cost of what it sells — whether that advantage is durable pricing power or a margin that can erode is the question the record is for. The operating margin has swung widely — from 3.1% to 16% — on a steadier 69% gross margin, so what moves it sits below the gross line, in operating spend and one-off charges more than in the cost of the product itself. Inventory runs near 24% of sales, so how fast it turns back into cash — and the risk of writing it down when demand softens — sits alongside the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has rarely cleared the cost of capital (median 4%, above 15% in 0 of 7 years). By owner earnings: roughly 18% of revenue reaches owners as cash, consistently. The cycle and the balance sheet decide this one; the worst year tells more than the median, and the rest is in the 10-K.
Every line is arithmetic on the company's filings, shown in full in the sections below.
Where the money comes from
read the 20-F →Revenue spreads across 7 regions, the largest United States at 52%.
- United States52%¥2.38T
- Europe and Canada23%¥1.06T
- Japan9%¥418.5B
- Latin America5%¥235.8B
- China4%¥191.7B
- Other3%¥128.8B
- Other4%¥171.7B
From the segment footnote of the company's own 20-F. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.
The record
Ten years of arithmetic, read across the cycle.
The record, 2017–2025
realized figures from each filing · older years to the left| 2017’17 | 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | TTMTTMMar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| ¥1.73T | ¥1.77T | ¥2.10T | ¥3.29T | ¥3.20T | ¥3.57T | ¥4.03T | ¥4.26T | ¥4.58T | ¥4.58T | RevenueRevenue |
| 68% | 72% | 69% | 67% | 69% | 69% | 69% | 67% | 66% | 66% | Gross marginGross mgn |
| ¥155.9B | ¥241.8B | ¥237.7B | ¥100.4B | ¥509.3B | ¥460.8B | ¥490.5B | ¥214.1B | ¥342.6B | ¥342.6B | Operating incomeOp. inc. |
| 9.0% | 13.7% | 11.3% | 3.1% | 15.9% | 12.9% | 12.2% | 5.0% | 7.5% | 7.5% | Operating marginOp. mgn |
| ¥114.9B | ¥186.9B | ¥135.2B | ¥44.2B | ¥376.0B | ¥230.1B | ¥317.0B | ¥144.1B | ¥107.9B | ¥107.9B | Net incomeNet inc. |
| 19% | 14% | -6% | — | -3% | 24% | 15% | — | 38% | 38% | Effective tax rateTax rate |
| Cash flow & returns | ||||||||||
| ¥261.4B | ¥377.9B | ¥328.5B | ¥669.8B | ¥1.01T | ¥1.12T | ¥977.2B | ¥716.3B | ¥1.06T | ¥1.06T | Operating cash flowOp. cash |
| ¥171.4B | ¥182.1B | ¥247.7B | ¥583.6B | ¥559.7B | ¥583.2B | ¥664.4B | ¥728.0B | ¥761.4B | ¥761.4B | DepreciationDeprec. |
| (¥25.0B) | ¥8.8B | (¥54.4B) | ¥41.9B | ¥75.3B | ¥309.9B | (¥4.3B) | (¥155.7B) | ¥187.9B | ¥187.9B | Working capital & otherWC & other |
| ¥61.7B | ¥67.0B | ¥77.7B | ¥127.1B | ¥111.2B | ¥123.3B | ¥140.7B | ¥175.4B | ¥200.8B | ¥200.8B | CapexCapex |
| 3.6% | 3.8% | 3.7% | 3.9% | 3.5% | 3.5% | 3.5% | 4.1% | 4.4% | 4.4% | Capex / revenueCapex/rev |
| ¥199.7B | ¥310.8B | ¥250.8B | ¥542.7B | ¥899.7B | ¥999.9B | ¥836.5B | ¥540.9B | ¥856.4B | ¥856.4B | Owner earningsOwner earn. |
| 11.5% | 17.6% | 12.0% | 16.5% | 28.1% | 28.0% | 20.8% | 12.7% | 18.7% | 18.7% | Owner earnings marginOE mgn |
| ¥199.7B | ¥310.8B | ¥250.8B | ¥542.7B | ¥899.7B | ¥999.9B | ¥836.5B | ¥540.9B | ¥856.4B | ¥856.4B | Free cash flowFCF |
| 11.5% | 17.6% | 12.0% | 16.5% | 28.1% | 28.0% | 20.8% | 12.7% | 18.7% | 18.7% | Free cash flow marginFCF mgn |
| ¥141.7B | ¥141.9B | ¥143.0B | ¥282.6B | ¥283.4B | ¥283.7B | ¥279.4B | ¥287.2B | ¥302.5B | ¥302.5B | Dividends paidDiv. paid |
| ¥23.1B | ¥18.8B | ¥1.2B | ¥3.7B | ¥2.1B | ¥77.5B | ¥26.9B | ¥2.3B | ¥51.9B | — | BuybacksBuybacks |
| — | 8% | 3% | — | 6% | 4% | 4% | 2% | 2% | 2% | ROICROIC |
| 6% | 9% | 3% | 1% | 7% | 4% | 5% | 2% | 2% | 2% | Return on equityROE |
| −1% | 2% | −0% | −5% | 2% | −1% | 1% | −2% | −3% | −3% | Retained to equityRetained/eq |
| Balance sheet | ||||||||||
| ¥319.5B | ¥294.5B | ¥702.1B | ¥637.6B | ¥966.2B | ¥849.7B | ¥533.5B | ¥457.8B | ¥385.1B | ¥385.1B | Cash & investmentsCash+inv |
| — | ¥420.2B | ¥741.9B | ¥757.0B | ¥783.1B | ¥696.6B | ¥649.4B | ¥668.4B | ¥709.5B | ¥709.5B | ReceivablesReceiv. |
| — | ¥212.9B | ¥919.7B | ¥759.6B | ¥753.9B | ¥853.2B | ¥986.5B | ¥1.21T | ¥1.22T | ¥1.22T | InventoryInvent. |
| — | ¥240.3B | ¥327.4B | ¥318.8B | ¥343.8B | ¥516.3B | ¥649.2B | ¥547.5B | ¥475.5B | ¥475.5B | Accounts payablePayables |
| — | ¥392.9B | ¥1.33T | ¥1.20T | ¥1.19T | ¥1.03T | ¥986.7B | ¥1.33T | ¥1.45T | ¥1.45T | Operating working capitalOper. WC |
| — | ¥1.08T | ¥2.99T | ¥2.47T | ¥2.71T | ¥2.59T | ¥2.40T | ¥2.56T | ¥2.52T | ¥2.52T | Current assetsCur. assets |
| — | ¥737.5B | ¥2.55T | ¥2.18T | ¥1.77T | ¥2.15T | ¥2.48T | ¥2.31T | ¥2.51T | ¥2.51T | Current liabilitiesCur. liab. |
| — | 1.5× | 1.2× | 1.1× | 1.5× | 1.2× | 1.0× | 1.1× | 1.0× | 1.0× | Current ratioCurr. ratio |
| — | ¥1.03T | ¥4.24T | ¥4.01T | ¥4.03T | ¥4.41T | ¥4.79T | ¥5.41T | ¥5.32T | ¥5.32T | GoodwillGoodwill |
| — | ¥4.11T | ¥13.79T | ¥12.82T | ¥12.91T | ¥13.18T | ¥13.96T | ¥15.11T | ¥14.25T | ¥14.25T | Total assetsAssets |
| — | ¥985.6B | ¥4.77T | ¥4.51T | ¥4.61T | ¥4.14T | ¥4.04T | ¥4.48T | ¥3.97T | ¥3.97T | Total debtDebt |
| — | ¥691.1B | ¥4.06T | ¥3.87T | ¥3.65T | ¥3.29T | ¥3.51T | ¥4.02T | ¥3.58T | ¥3.58T | Net debt / (cash)Net debt |
| 6.7× | 7.6× | 2.9× | 0.6× | 2.0× | 2.8× | 2.9× | 1.0× | 1.6× | 1.6× | Interest coverageInt. cov. |
| ¥1.95T | ¥2.00T | ¥5.18T | ¥4.72T | ¥5.17T | ¥5.68T | ¥6.35T | ¥7.27T | ¥6.94T | ¥6.94T | Shareholders’ equityEquity |
| Per share | ||||||||||
| 781M | 781M | 961M | 1.56B | 1.56B | 1.56B | 1.55B | 1.56B | 1.58B | 1.59B | Shares out (diluted)Shares |
| ¥2217.46 | ¥2267.55 | ¥2181.25 | ¥2113.52 | ¥2047.25 | ¥2282.70 | ¥2595.34 | ¥2725.41 | ¥2901.79 | ¥2879.76 | Revenue / shareRev/sh |
| ¥147.15 | ¥239.35 | ¥140.61 | ¥28.41 | ¥240.72 | ¥147.14 | ¥204.29 | ¥92.09 | ¥68.36 | ¥67.84 | EPS (diluted)EPS |
| ¥255.67 | ¥398.11 | ¥260.85 | ¥348.49 | ¥576.01 | ¥639.50 | ¥539.05 | ¥345.76 | ¥542.40 | ¥538.29 | Owner earnings / shareOE/sh |
| ¥255.67 | ¥398.11 | ¥260.85 | ¥348.49 | ¥576.01 | ¥639.50 | ¥539.05 | ¥345.76 | ¥542.40 | ¥538.29 | Free cash flow / shareFCF/sh |
| ¥181.40 | ¥181.72 | ¥148.68 | ¥181.47 | ¥181.41 | ¥181.43 | ¥180.06 | ¥183.57 | ¥191.59 | ¥190.14 | Dividends / shareDiv/sh |
| ¥78.94 | ¥85.81 | ¥80.79 | ¥81.61 | ¥71.19 | ¥78.83 | ¥90.64 | ¥112.13 | ¥127.18 | ¥126.21 | Cap. spending / shareCapex/sh |
| ¥2495.17 | ¥2558.14 | ¥5389.61 | ¥3033.31 | ¥3311.79 | ¥3634.80 | ¥4094.65 | ¥4649.09 | ¥4392.43 | ¥4359.08 | Book value / shareBVPS |
The diluted share count moved ×1.62 into 2020 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.
| 8-yr | 5-yr | |
|---|---|---|
| Revenue / share | +3.4%/yr | +6.5%/yr |
| Owner earnings / share | +9.9%/yr | +9.3%/yr |
| EPS | −9.1%/yr | +19.2%/yr |
| Dividends / share | +0.7%/yr | +1.1%/yr |
| Capital spending / share | +6.1%/yr | +9.3%/yr |
| Book value / share | +7.3%/yr | +7.7%/yr |
The record, charted
FY2017–2025Each measure over its full record; the current point and the worst year marked.
Owner earnings vs. net income
Owner earningsNet incomeThe accountant's number, and the cash an owner can take; the gap is the tell.
Where the cash went
ReinvestBuybacksDividendsAcquisitionsRetainedEach year's operating cash, by what management did with it: the mix, and how it drifts.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business turned ¥107.9B of profit into ¥856.4B of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Reported net income | ¥107.9B | ¥144.1B | ¥317.0B | ¥230.1B | ¥376.0B |
| Depreciation & amortizationnon-cash charge added back | +¥761.4B | +¥728.0B | +¥664.4B | +¥583.2B | +¥559.7B |
| Working capital & othertiming of cash in and out, other non-cash items | +¥187.9B | −¥155.7B | −¥4.3B | +¥309.9B | +¥75.3B |
| Cash from operations | ¥1.06T | ¥716.3B | ¥977.2B | ¥1.12T | ¥1.01T |
| Capital expenditurecash put back in to keep running and to grow | −¥200.8B | −¥175.4B | −¥140.7B | −¥123.3B | −¥111.2B |
| Owner earnings | ¥856.4B | ¥540.9B | ¥836.5B | ¥999.9B | ¥899.7B |
| Owner-earnings marginowner earnings ÷ revenue | 19% | 13% | 21% | 28% | 28% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
Will it survive?
- ThinOperating income ¥342.6B ÷ interest expense ¥210.1B
What this means
Operating profit covers interest, but with little room. A bad year, a refinancing at higher rates, or a revenue wobble closes the gap fast.
- How heavy is the debt, net of cash? ¥3.58T · 10.5× operating profitHeavy net debtCash ¥385.1B − debt ¥3.97T
What this means
Netting ¥385.1B of cash and short-term investments against ¥3.97T of debt leaves ¥3.58T owed, about 10.5× a year's operating profit (11.6× on the gross debt, before the cash). Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Long (60+ days)DSO 57 + DIO 281 − DPO 110 days
What this means
Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.
Is it a good business?
- Below average through the cycle7-yr median, range 2%–8%; 2% latest = NOPAT ¥211.4B ÷ invested capital ¥10.52TIndustry peers: median 19%
What this means
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 7 years (it ran 2% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- High through the cycle9-yr median margin, range 12%–28%; latest ¥856.4B = operating cash ¥1.06T − maintenance capex ¥200.8BIndustry peers: median 23%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 19% of revenue this year, a 18% median across 9 years.
- Cash-backedCash from ops ¥1.06T ÷ net income ¥107.9B
What this means
How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.
How is the cash used?
- Returns about halfDividends + buybacks ¥354.4B ÷ Owner Earnings ¥856.4B
What this means
Of ¥856.4B Owner Earnings, ¥354.4B (41%) went back to shareholders, ¥302.5B dividends, ¥51.9B buybacks. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.
- Investing or harvesting? 0.26×HarvestingCapex ¥200.8B ÷ depreciation ¥761.4B
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Graham’s defensive tests · 2 of 5 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size —Revenue ≥ $2B (a dollar floor) · ¥4.58T
What this means
Big enough to weather a storm. Graham's floor is a dollar figure — about $2B of revenue as a conservative modern stand-in. This company reports in its home currency and we carry no exchange rate, so we show the figure and leave the size bar for you to apply rather than convert it with a number we don't have.
- Strong liquidity MissCurrent ratio ≥ 2× · 1.01×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt MissDebt ≤ working capital · ¥3.97T vs ¥14.7B WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Earnings stability PassA profit every year (9-yr record) · no losses
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record PassUninterrupted dividends · paid every year (9)
What this means
An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.
- Earnings growth NearEarnings +33% over the record · +30%
What this means
At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are ¥119.22/share (latest year ¥67.84), the averaged base the calculator's gate runs on, and book value is ¥4359.08/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2017–2025
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 9 of 9
What this means
Never lost money over the record, the earnings stability Graham insisted on.
- Return on capital ≥ 15% 0 of 8 yrs
What this means
A moat shows up as a high return on invested capital that holds year after year, not one good vintage.
- Operating margin 11% → 8% (3-yr avg ends)
In the filing’s words The words explain the slip: the filing names price competition rather than pricing actions of its own — a business that looks to take its price, not set it.
What this means
Through the cycle the operating margin slipped — about 11% early to 8% lately, median 11% — competition or costs are biting in.
- Reinvestment, incremental ROIC 2%
What this means
Reinvested capital came back at only a modest incremental return — near the cost of capital, where extra growth adds little per dollar. The record shows whether it is a soft stretch or a thinning moat.
- Owner earnings growth +13%/yr
What this means
Owner earnings grew about 13% a year over the record.
- Worst year 2020 · 3.1% op. margin
What this means
Stayed profitable even in its hardest year, the resilience that survives recessions.
- Dividend record rising
What this means
Paid and raised the dividend across the record, the continuity Graham prized.
Does AI threaten the moat?
Low contestabilityThe moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.
The filing raises AI among its risks, but in other terms (security, regulation, energy or the like), not as a competitor to its product; it frames AI mainly as a capability.
AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat, and the company is using it that way.
Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.
All figures as filed; the source filing is linked above.
Current Position
as of fiscal year-end, Mar 31, 2025Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments¥385.1B
- Receivables¥709.5B
- Inventory¥1.22T
- Other current assets¥209.3B
- Accounts payable¥475.5B
- Other current liabilities¥2.03T
From the company's latest filing.
How the cash was used, 2017–2025
Over the record, the business generated ¥6.52T of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.
- Reinvested¥1.08T · 17%
- Dividends¥2.15T · 33%
- Buybacks¥207.6B · 3%
- Retained (debt / cash)¥3.08T · 47%
- Returned to owners¥2.35T
43% of the owner earnings the business produced over the span, ¥2.15T as dividends and ¥207.6B as buybacks.
- Average price paid for buybacks—
Buybacks ran ¥207.6B over the span, but the filings don't tag the share count needed to deduce the average price paid.
- Net change in share count103.7%
The diluted count rose from 781M to 1591M: issuance (stock pay, deals) outran any buybacks, so owners were diluted on net.
- Dividend record¥191.59/sh
Paid in 9 of the years on record, the per-share dividend growing about 1% a year. It was never cut over the span.
Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.
Acquisitions & goodwill
from the balance sheet & the 9-year cash-flow recordGoodwill grows only when a company acquires and falls only when it concedes it overpaid. The size of that bet, the cash put into buying rather than building, and how much has already been written off.
None written down over the record; the goodwill is still carried at full cost. That is the deals holding their value on the books so far; whether they keep doing so is the test an owner watches, since the write-down, when it comes, is the admission the price was too high.
Goodwill, acquired intangibles and equity from the latest balance sheet; acquisition spend and write-downs summed across the 9-year record, from the company's own filings.
Inverting the record
Invert: instead of why Takeda Pharmaceutical Company Limited is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2017–2025.
1 of the 3 tests turned up something to look into; the other 2 came back clean.
- Look hereDid the share count rise anyway?103.7%
Diluted shares grew 103.7% over 2017–2025, even as the company spent ¥207.6B on buybacks. The repurchases were outrun by issuance — to staff, in a raise, or in a deal — and the filing says which; owners' slice still shrank. Read the buyback line beside this one, not on its own.
- Is it less profitable than it was?
- Did reported profit become cash?
Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.
Peers, Pharmaceuticals
The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.
| Company | Revenue | Gross margin | Op. margin | ROIC | Owner earn. margin |
|---|---|---|---|---|---|
| TAKTakeda Pharmaceutical Company Limited | ¥4.58T | 69% | 11.3% | 4% | 18% |
| JNJJohnson & Johnson | $94.2B | 67% | 23.8% | 22% | 23% |
| LLYEli Lilly and Company | $65.2B | 78% | 24.0% | 27% | 20% |
| MRKMerck & Company Inc. Common Stock (new) | $65.0B | 70% | 25.9% | 19% | 21% |
| PFEPfizer Inc. | $62.6B | 75% | 26.1% | 11% | 28% |
| ABBVAbbVie Inc. | $61.2B | 70% | 28.0% | 21% | 38% |
| BMYBristol-Myers Squibb Company | $48.2B | 72% | 18.9% | 12% | 28% |
| ABTAbbott Laboratories | $44.3B | 56% | 15.8% | 11% | 17% |
| Group median | — | 70% | 23.9% | 15% | 22% |
The price
What a price has to assume.
What the price implies
reverse-DCFEnter the US price, in dollars: the NYSE/Nasdaq quote you hold. Per the filing's own cover, “American Depositary Shares (ADSs), with each ADS representing a one-half interest in an ordinary”; Takeda Pharmaceutical Company Limited reports in JPY, so every figure in this tool is stated per ADS and translated at JPY 1 = $0.0062 (2026-07-17, reference rate) so your dollar quote reconciles exactly. The record tables elsewhere on this page remain as filed, in JPY.
Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Takeda Pharmaceutical Company Limited has delivered.
Through the cycle, Takeda Pharmaceutical Company Limited earns about $5.0B on its 17.6% median owner-earnings margin. This year’s 18.7% margin runs in line with that. Normalize, below, values the price on that through-cycle figure rather than the latest year.
—
9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Owner earnings $5.3B on 3182M shares outstanding, the balance-sheet count at 2025-03-31; net debt $22.1B. The base is the latest year by default; Normalize values it on the through-cycle median owner-earnings margin (to avoid paying on a peak year). Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Manual order: ← TAC its page in the Manual TAL →
Industry order: ← SXTC the Pharmaceuticals chapter TBPH →